Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03900403 · ClinicalTrials.gov registry record · NA

Influence of Walnut Intake on Vascular Function and Metabolism

A NA study, sponsored by University of California, Davis.

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT03900403 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03900403, a NA study, has completed, sponsored by University of California, Davis.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

This study seeks to confirm and extend previous finding that four weeks of daily intake of 40 g of walnuts improve microvascular function, increasing the reactive hyperemia index (RHI), effects which were greatest in individuals with the worst initial RHI and correlating to circulating levels of vasoactive plasma epoxides. The current trial will enroll postmenopausal women who are at risk for cardiovascular disease due to their menopausal status and increased central adiposity. The initial trial focused on non-esterified (i.e. plasma) derived oxylipins, but substantial and unique changes were also observed in the esterified lipoprotein pool. The current study will add the esterified lipoprotein pool, important, as the mechanisms by which walnut intake influences endothelial function are currently undefined, but may include lipoprotein induced modulation of vascular hemostasis. As a secondary objective, primary metabolism and urolithin metabotype will be analyzed as a way to capture the influence of potential differences in habitual diet and metabolism on physiologic response. Therefore, this study will combine measures of cardiovascular physiology, metabolomics, and walnut-derived metabolite analyses to assess the 12 week influence of 40 g of daily walnut intake on the health of overweight and obese postmenopausal women.

Interventions

  • OTHER Walnut Intake

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2019-09-01
Est. Completion 2023-06-14
Phase NA

Sponsor

University of California, Davis

657 total trials

What the Registry Record Tells You About NCT03900403

The ClinicalTrials.gov registry entry for NCT03900403 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Walnut Intake is the first listed.

NCT03900403 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03900403 about?

NCT03900403 is a clinical study titled "Influence of Walnut Intake on Vascular Function and Metabolism". This study seeks to confirm and extend previous finding that four weeks of daily intake of 40 g of walnuts improve microvascular function, increasing the reactive hyperemia index (RHI), effects which were greatest in individuals with the worst initial RHI and correlating to circulating levels of vas...

What is the current status of trial NCT03900403?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2019-09-01. Estimated completion is 2023-06-14.

What interventions are being tested in trial NCT03900403?

The interventions under investigation include: Walnut Intake (OTHER).

Who is sponsoring clinical trial NCT03900403?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.